Characteristic of molecular subtypes based on PANoptosis-related genes and experimental verification of hepatocellular carcinoma

被引:0
作者
Ren, Haitao [1 ]
Kang, Na [2 ]
Yin, Shuan [3 ]
Xu, Chen [4 ]
Qu, Tengfei [5 ]
Dai, Dongdong [5 ]
机构
[1] Qingdao Univ, Dept Intervent Med, Affiliated Hosp, Qingdao 266071, Shangdong, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Operating Room, Qingdao 266071, Shangdong, Peoples R China
[3] Qingdao Univ, Dept Pediat, Affiliated Hosp, Qingdao 266071, Shangdong, Peoples R China
[4] Qingdao Univ, Dept Infect Dis, Affiliated Hosp, Qingdao 266071, Shangdong, Peoples R China
[5] Qingdao Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp, Qingdao 266071, Shangdong, Peoples R China
来源
AGING-US | 2023年 / 15卷 / 10期
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; PANoptosis-related genes; risk model; immune infiltration; molecular subtypes; EOSINOPHILS; SURVIVAL;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Hepatocellular carcinoma (HCC) is a type of liver cancer that originates from liver cells. It is one of the most common types of liver cancer and a leading cause of cancer-related death worldwide. Early detection and treatment can improve the HCC prognosis. Therefore, it is necessary to further improve HCC markers and risk stratification. PANoptosome is a cytoplasmic polymer protein complex that regulates a proinflammatory programmed cell death pathway called "PANoptosis". The role of PANoptosis in HCC remains unclear. In this study, the molecular changes of PANoptosis related genes (PAN-RGs) in HCC were systematically evaluated. We characterized the heterogeneity of HCC by using consensus clustering to identify two distinct subtypes. The two subtypes showed different survival rate, biological function, chemotherapy drug sensitivity and immune microenvironment. After identification of PAN-RG differential expression genes (DEGs), a prognostic model was established by Cox regression analysis using minimum absolute contraction and selection operator (LASSO), and its prognostic value was verified by Cox regression analysis, Kaplan-Meier curve and receiver operating characteristic (ROC) curve. Our own specimens were also used to further validate the prognostic significance and possible clinical value of the selected targets. Subsequently, we conducted a preliminary discussion on the reasons for the influence of the model on the prognosis through TME analysis, drug resistance analysis, TMB analysis and other studies. This study provides a new idea for individualized and precise treatment of HCC.
引用
收藏
页码:4159 / 4181
页数:23
相关论文
共 63 条
  • [1] IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression
    Aqbi, Hussein F.
    Wallace, Matthew
    Sappal, Samay
    Payne, Kyle K.
    Manjili, Masoud H.
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2018, 103 (06) : 1219 - 1223
  • [2] Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis
    Chen, Minting
    Wu, Hsin Ling
    Wong, Tsz Sin
    Chen, Baisen
    Gong, Rui-Hong
    Wong, Hoi Leong Xavier
    Xiao, Haitao
    Bian, Zhaoxiang
    Kwan, Hiu Yee
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis
    Chen, Shi-Lu
    Liu, Li-Li
    Lu, Shi-Xun
    Luo, Rong-Zhen
    Wang, Chun-Hua
    Wang, Hong
    Cai, Shao-Hang
    Yang, Xia
    Xie, Dan
    Zhang, Chris Zhiyi
    Yun, Jing-Ping
    [J]. MOLECULAR ONCOLOGY, 2017, 11 (09): : 1225 - 1240
  • [4] The emerging roles of TRIM21 in coordinating cancer metabolism, immunity and cancer treatment
    Chen, Xintian
    Cao, Menghan
    Wang, Pengfei
    Chu, Sufang
    Li, Minle
    Hou, Pingfu
    Zheng, Junnian
    Li, Zhongwei
    Bai, Jin
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells
    Cheng, Jin-Shiung
    Tsai, Wei-Lun
    Liu, Pei-Feng
    Goan, Yih-Gang
    Lin, Chih-Wen
    Tseng, Ho-Hsing
    Lee, Cheng-Hsin
    Shu, Chih-Wen
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [6] Comprehensive Analysis of the Prognostic Values of the TRIM Family in Hepatocellular Carcinoma
    Dai, Weiyu
    Wang, Jing
    Wang, Zhi
    Xiao, Yizhi
    Li, Jiaying
    Hong, Linjie
    Pei, Miaomiao
    Zhang, Jieming
    Yang, Ping
    Wu, Xiaosheng
    Tang, Weimei
    Jiang, Xiaoling
    Jiang, Ping
    Xiang, Li
    Li, Aimin
    Lin, Jianjiao
    Liu, Side
    Wang, Jide
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma
    De Ponti, Aurora
    Wiechert, Lars
    Schneller, Doris
    Pusterla, Tobias
    Longerich, Thomas
    Hogg, Nancy
    Vogel, Arndt
    Schirmacher, Peter
    Hess, Jochen
    Angel, Peter
    [J]. CANCER LETTERS, 2015, 369 (02) : 396 - 404
  • [8] SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway
    Ding, Jun
    Qin, Daming
    Zhang, Yong
    Li, Qinghe
    Li, Yi
    Li, Jinmao
    [J]. MOLECULAR MEDICINE REPORTS, 2020, 21 (03) : 1251 - 1257
  • [9] A new dawn for eosinophils in the tumour microenvironment
    Grisaru-Tal, Sharon
    Itan, Michal
    Klion, Amy D.
    Munitz, Ariel
    [J]. NATURE REVIEWS CANCER, 2020, 20 (10) : 594 - 607
  • [10] Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial
    He, MinKe
    Li, QiJiong
    Zou, RuHai
    Shen, JingXian
    Fang, WanQiang
    Tan, GuoSheng
    Zhou, YuanMin
    Wu, XiaoPing
    Xu, Li
    Wei, Wei
    Le, Yong
    Zhou, ZhongGuo
    Zhao, Ming
    Guo, Ying
    Guo, RongPing
    Chen, MinShan
    Shi, Ming
    [J]. JAMA ONCOLOGY, 2019, 5 (07) : 953 - 960